WHWK

Whitehawk Therapeutics, Inc. (WHWK) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company. Following the divestiture of its legacy FYARRO business in March 2025, the Company's operations now focus exclusively on the development and commercialization of a portfolio of three next-generation antibody drug conjugates (ADCs) licensed from WuXi Biologics. The Company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Q1 2025 net income was driven by an $87.4 million gain on the sale of the FYARRO business. Q1 2026 reflects no product sales as the FYARRO business was divested in March 2025.

Material Changes vs. Prior Period

• Revenue Elimination: Product sales dropped to $0 from $7.1 million in Q1 2025 due to the completion of the FYARRO Divestiture on March 25, 2025. The Company no longer has commercial revenue streams.
• Net Loss vs. Income: The Company reported a net loss of $22.2 million compared to net income of $73.0 million in the prior year. The prior year's income was non-recurring, primarily attributable to the gain on the sale of the FYARRO business.
• Expense Shift: Research and Development (R&D) expenses increased to $17.2 million from $8.8 million, driven by $5.3 million in development milestone expenses related to the WuXi Biologics license and increased clinical development costs for the ADC portfolio. Selling, General, and Administrative (SG&A) expenses decreased to $6.3 million from $12.8 million, reflecting the reduction of commercialization costs associated with the divested FYARRO business.
• Liquidity Position: Cash and short-term investments decreased by approximately $104.5 million to $123.0 million, primarily due to operating cash burn and the absence of the large cash inflow from the FYARRO divestiture that occurred in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management believes current cash, cash equivalents, and short-term investments ($123.0 million) are sufficient to fund operations into 2028. The Company expects to continue incurring significant net losses as it advances its ADC pipeline.
• Pipeline Progress:
  • HWK-007 (PTK7-targeted): Phase 1 trial initiated in Q1 2026; actively recruiting. Data readout expected in H1 2027.
  • HWK-016 (MUC16-targeted): IND cleared by FDA in Q1 2026; Phase 1 trial actively recruiting. Data readout expected in H1 2027.
  • HWK-206 (SEZ6-targeted): IND submission anticipated in mid-2026.
• Key Risks:
  • Capital Requirements: The Company will require additional financing to complete development and commercialization. Failure to raise capital could force delays or elimination of programs.
  • Third-Party Reliance: The Company relies on WuXi Biologics and Hangzhou DAC (both based in China) for manufacturing and technology. Geopolitical tensions and U.S. legislation (e.g., the BIOSECURE Act) pose risks to the supply chain.
  • Regulatory Uncertainty: No products are currently approved. Success depends on obtaining regulatory approval for the ADC portfolio, which is subject to clinical trial risks and regulatory changes.

Investor Verification Checklist

• Verify the timeline and milestones for the Phase 1 trials of HWK-007 and HWK-016, specifically the expected H1 2027 data readouts.
• Assess the impact of the BIOSECURE Act and U.S.-China trade relations on the Company's reliance on WuXi Biologics and Hangzhou DAC for manufacturing.
• Monitor the Company's cash burn rate against the $123.0 million liquidity position to validate the "into 2028" runway estimate.
• Review the terms of the WuXi Biologics license agreement, specifically the $265 million in potential development milestones and royalty obligations.
• Confirm the status of the $75.0 million "at-the-market" (ATM) sales agreement with Cowen, noting that no shares have been sold under this agreement as of March 31, 2026.